Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 14 years, with Q2 2025 value amounting to $166.9 million.

  • Lifecore Biomedical, Inc. \De\'s Total Non-Current Liabilities fell 443.15% to $166.9 million in Q2 2025 from the same period last year, while for May 2025 it was $166.9 million, marking a year-over-year decrease of 443.15%. This contributed to the annual value of $166.9 million for FY2025, which is 443.15% down from last year.
  • Lifecore Biomedical, Inc. \De\'s Total Non-Current Liabilities amounted to $166.9 million in Q2 2025, which was down 443.15% from $166.4 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s Total Non-Current Liabilities' 5-year high stood at $301.6 million during Q1 2021, with a 5-year trough of $153.6 million in Q2 2023.
  • Its 5-year average for Total Non-Current Liabilities is $196.1 million, with a median of $177.9 million in 2022.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 3994.57% in 2022, then surged by 1843.35% in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Total Non-Current Liabilities stood at $264.0 million in 2021, then dropped by 22.47% to $204.6 million in 2022, then decreased by 22.07% to $159.5 million in 2023, then increased by 8.06% to $172.3 million in 2024, then decreased by 3.14% to $166.9 million in 2025.
  • Its last three reported values are $166.9 million in Q2 2025, $166.4 million for Q1 2025, and $172.3 million during Q4 2024.